04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
00:34 , Nov 21, 2018 |  BC Extra  |  Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

In a deal that will make Idorsia Ltd. (SIX:IDIA) its largest shareholder, Santhera Pharmaceuticals Holding AG (SIX:SANN) gained an option to exclusively in-license a second Duchenne muscular dystrophy candidate: vamorolone (VBP15). Santhera CEO Thomas Meier...
20:11 , Apr 26, 2018 |  BC Innovations  |  Translation in Brief

Modulating metabolism in MS

Johns Hopkins University researchers showed in Science Tecfidera dimethyl fumarate blocks aerobic glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shedding light on how the multiple sclerosis drug suppresses immune activation and suggesting metabolism as a target...
18:22 , Apr 13, 2018 |  BC Extra  |  Preclinical News

NCI identifies new lymphoma subtypes

A New England Journal of Medicine paper out of NIH's National Cancer Institute revealed new subtypes of diffuse large B cell lymphomas (DLBCL) that could lead to more targeted therapeutic strategies. The report adds to...
17:17 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for omaveloxolone in mitochondrial myopathies

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported top-line data from the Phase II MOTOR trial in 53 patients with mitochondrial myopathies showing that omaveloxolone (oral RTA 408) missed the primary endpoint of improving peak workload during exercise...
15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
17:33 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the U.S. Phase I/II MoveDMD trial in steroid-naïve Duchenne muscular...
22:55 , Feb 13, 2018 |  BC Extra  |  Clinical News

Catabasis gains on 60-week DMD data

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) was up $0.31 (25%) to $1.56 on Tuesday after reporting that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the...
01:53 , Jan 25, 2018 |  BC Innovations  |  Translation in Brief

No TNFα for transplants

A University of Toronto team has shown that inhibiting TNFα enhances the engraftment success of hematopoietic stem cell transplants in mice and plans to test the strategy in the clinic using Enbrel etanercept within a...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...